Homing of endogenous stem/progenitor cells for in situ tissue regeneration: Promises, strategies, and translational perspectives

被引:285
作者
Chen, Fa-Ming [1 ,2 ]
Wu, Li-An [2 ,3 ]
Zhang, Min [4 ]
Zhang, Rong [5 ]
Sun, Hai-Hua [5 ]
机构
[1] Fourth Mil Med Univ, Sch Stomatol, Dept Periodontol & Oral Med, Xian 710032, Shaanxi, Peoples R China
[2] Fourth Mil Med Univ, Sch Stomatol, Translat Res Grp, Xian 710032, Shaanxi, Peoples R China
[3] Fourth Mil Med Univ, Sch Stomatol, Dept Paediat Dent, Xian 710032, Shaanxi, Peoples R China
[4] Fourth Mil Med Univ, Sch Stomatol, Dept Gen Dent & Emergency, Xian 710032, Shaanxi, Peoples R China
[5] Fourth Mil Med Univ, Sch Stomatol, Dept Operat Dent & Endodont, Xian 710032, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Cell homing; Tissue engineering; Endogenous regenerative technology; Biomimetic design; Drug delivery; Translational medicine; MESENCHYMAL STEM-CELLS; ENDOTHELIAL PROGENITOR CELLS; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR-DELIVERY; BONE-MARROW-CELLS; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; IMPROVES CARDIAC-FUNCTION; NEURAL STEM; PERIODONTAL-LIGAMENT;
D O I
10.1016/j.biomaterials.2010.12.032
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Stem cell-based therapy has been one of the best documented approaches in regenerative medicine, promising cures for a multitude of diseases and disorders. However, the ex vivo expansion of stem cells and their in vivo delivery are restricted by the limited availability of stem cell sources, the excessive cost of commercialization, and the anticipated difficulties of clinical translation and regulatory approval. An alternative to adoptively transferred stem cells are cell populations already present in a patient's body, including stem/progenitor cells, which can be actively attracted to sites of injury. This technique, known as endogenous cell homing, has the potential to provide new therapeutic options for in situ tissue regeneration. Such options would be less costly and complex than approaches that require substantial ex vivo cell manipulation and that use artificial vehicles for cell delivery. Tissue regeneration methods that rely on endogenous stem/progenitor cell homing, local tissue responses, and functional stimulation thus offer new insights into in vivo tissue engineering and hold great promise for the future of translational medicine. Although such methods that take advantage of the latent endogenous regenerative potential of the patient are promising for the repair of damaged tissue, they are in need of further experimental support before application in late-stage diseases or severe tissue injury. This review is not meant to be exhaustive but gives a brief outlook on the promises, strategies, and current applications of endogenous stem cell homing for in situ tissue regeneration, with particular emphasis placed upon pharmacological means based on cell-instructive scaffolds and release technology to direct cell mobilization and recruitment. In the future these exciting paradigms are likely to help reconcile the clinical and commercial pressures in regenerative medicine. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3189 / 3209
页数:21
相关论文
共 239 条
[1]   Epimorphic regeneration approach to tissue replacement in adult mammals [J].
Agrawal, Vineet ;
Johnson, Scott A. ;
Reing, Janet ;
Zhang, Li ;
Tottey, Stephen ;
Wang, Gang ;
Hirschi, Karen K. ;
Braunhut, Susan ;
Gudas, Lorraine J. ;
Badylak, Stephen F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (08) :3351-3355
[2]   The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche [J].
Aicher, Alexandra ;
Kollet, Orit ;
Heeschen, Christopher ;
Liebner, Stefan ;
Urbich, Carmen ;
Ihling, Christian ;
Orlandi, Alessia ;
Lapidot, Tsvee ;
Zeiher, Andreas M. ;
Dimmeler, Stefanie .
CIRCULATION RESEARCH, 2008, 103 (08) :796-803
[3]  
Allegra A, 2009, J NEPHROL, V22, P463
[4]   Potential of stem cell based therapy and tissue engineering in the regeneration of the central nervous system [J].
An, Yihua ;
Tsang, Kent K. S. ;
Zhang, Han .
BIOMEDICAL MATERIALS, 2006, 1 (02) :R38-R44
[5]  
Aoki J, 2005, J AM COLL CARDIOL, V45, p51A
[6]   Therapeutic Applications of Mesenchymal Stem Cells to Repair Kidney Injury [J].
Asanuma, Hiroshi ;
Meldrum, Daniel R. ;
Meldrum, Kirstan K. .
JOURNAL OF UROLOGY, 2010, 184 (01) :26-33
[7]   Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy [J].
Askari, A ;
Unzek, S ;
Goldman, CK ;
Ellis, SG ;
Thomas, JD ;
DiCorleto, PE ;
Topol, EJ ;
Penn, MS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (10) :1908-1914
[8]   Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy [J].
Askari, AT ;
Unzek, S ;
Popovic, ZB ;
Goldman, CK ;
Forudi, F ;
Kiedrowski, M ;
Rovner, A ;
Ellis, SG ;
Thomas, JD ;
DiCorleto, PE ;
Topol, EJ ;
Penn, MS .
LANCET, 2003, 362 (9385) :697-703
[9]   Transcoronary transplantation of progenitor cells after myocardial infarction [J].
Assmus, Birgit ;
Honold, Joerg ;
Schaechinger, Volker ;
Britten, Martina B. ;
Fischer-Rasokat, Ulrich ;
Lehmann, Ralf ;
Teupe, Claudius ;
Pistorius, Katrin ;
Martin, Hans ;
Abolmaali, Nasreddin D. ;
Tonn, Torsten ;
Dimmeler, Stefanie ;
Zeiher, Andreas M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (12) :1222-1232
[10]   Tissue-engineered autologous bladders for patients needing cystoplasty [J].
Atala, A ;
Bauer, SB ;
Soker, S ;
Yoo, JJ ;
Retik, AB .
LANCET, 2006, 367 (9518) :1241-1246